Abbott Vascular has received CE Mark approval for a 2.25 mm version of its Xience V everolimus-eluting coronary stent system.
The addition of the 2.25 mm stent to the Xience V portfolio gives physicians access to a wider range of stent sizes for treating a variety of patient types, according to the Abbott Park, Ill.-based Abbott.
“Lesions in small vessels tend to be more complex and challenging to treat, so it's important to have a drug-eluting stent with proven clinical benefits that can be easily delivered to the diseased area of the vessel,” said Charles Simonton, MD, divisional vice president, medical affairs and chief medical officer, Abbott Vascular.
The 2.25 mm version of the Xience V stent has been launched in the majority of European markets and select countries in Asia and Latin America, Abbott reported. In addition to the 2.25 mm stent, the company said that its Xience V is available in stent diameters of 2.5 mm, 2.75 mm, 3 mm, 3.5 mm and 4 mm for lesions 28 mm or shorter.